Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
9.82
-0.34 (-3.35%)
At close: Nov 22, 2024, 4:00 PM
9.74
-0.08 (-0.81%)
After-hours: Nov 22, 2024, 7:59 PM EST

Company Description

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.

The company is headquartered in Toronto, Canada.

Cybin Inc.
Cybin logo
Country Canada
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 50
CEO Douglas Drysdale

Contact Details

Address:
100 King Street West, Suite 5600
Toronto, ON M5X 1C9
Canada
Website cybin.com

Stock Details

Ticker Symbol CYBN
Exchange NYSEAMERICAN
Fiscal Year April - March
Reporting Currency CAD
CIK Code 0001833141
CUSIP Number 23256X100
ISIN Number CA23256X1006
SIC Code 2834

Key Executives

Name Position
Douglas L. Drysdale Chief Executive Officer
Eric So L.L.B. Co-Founder, President and Executive Chairman
Paul Glavine Co-Founder, Chief Growth Officer and Director
Greg Cavers Chief Financial Officer
Aaron Bartlone Chief Operating Officer
George Tziras Chief Business Officer and Director
John Kanakis Co-Founder
Dr. Alex L. Nivorozhkin Ph.D. Chief Scientific Officer
Lori Challenger Chief Compliance, Ethics and Administrative Officer
Gabriel Fahel Chief Legal Officer and Corporate Secretary

Latest SEC Filings

Date Type Title
Nov 18, 2024 6-K Report of foreign issuer
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 6-K Report of foreign issuer
Nov 13, 2024 6-K Report of foreign issuer
Nov 1, 2024 6-K Report of foreign issuer
Oct 24, 2024 6-K Report of foreign issuer
Oct 3, 2024 6-K Report of foreign issuer
Oct 1, 2024 6-K Report of foreign issuer
Sep 24, 2024 6-K Report of foreign issuer